Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P716

ICEECE2012 Poster Presentations Diabetes (248 abstracts)

Clinical and Patient Reported Outcomes over the 24 Months of Insulin Therapy in Patients with Type 2 Diabetes in Greece: Data from The Instigate Study

K. Aloumanis 1 , M. Benroubi 2 , S. Sourmeli 1 & V. Drossinos 1

General Hospital, Athens, Greece.

Aims: We present final Hellenic data from the INSTIGATE study which assessed direct costs, resource utilisation, and clinical outcomes in the first 24 months of insulin therapy in type 2 diabetic (T2D) patients.

Methods: INSTIGATE was a prospective European observational study of patients with type 2 diabetes who had initiated insulin during usual care. Data were collected at baseline, when subjects initiated insulin (visit T1), then 3 (T2), 6 (T3), 12 (T4), 18 (T5) and 24 months (T6) later.

Results: The data presented here is for the 237 patients with Baseline, 6 and 12 month visits; at 18 and 24 months data were available from 229 and 227 patients respectively.

Following insulin initiation mean HbA1c improved from (SD) 9.65(1.63)% at baseline to 7.44(1.06)%, 7.39(1.15)%, 7.28(0.96)% and 7.14(0.85)% at 6, 12, 18 and 24 months respectively. Mean fasting blood glucose (FBG) improved from (SD) 12.8(3.9) mmol/l to 7.8(2.2) mmol/l, 7.8(2.4) mmol/l, 7.5(2.1) mmol/l and 7.3(2.1) mmol/l over the same period. Mean BMI (SD) was 28.2(4.7) kg/m2 at baseline up to 29.4(4.6) kg/m2 at 24 months. Patients reporting at least one hypoglycaemic episode were 3.0% (in the three months prior to insulin initiation) 29.1% (in the six months after initiation) and above 20% thereafter. Health status, measured by EQ-5D visual analogue scale score, improved from baseline to 6, 12, 18 and 24 months, the highest improvement being from baseline up to 6 months after insulin initiation.

Conclusions: Greek patients initiated insulin when HbA1c is by much higher than recommended by international guidelines; yet their glycaemic control improved in the 6 months following initiation, the best improvement being observed from baseline to 6 months. Mean health-related quality-of-life scores also improved, however there was an increase in the number of patients reporting hypoglycaemia.

Declaration of interest: I fully declare a conflict of interest. Details below

Funding: This work was supported, however funding details unavailable.

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.